Related references
Note: Only part of the references are listed.Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigenesis
Alisha R. Yallowitz et al.
MOLECULAR CANCER RESEARCH (2015)
Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth
Jiajun Zhu et al.
NATURE (2015)
Tumor suppressor p53 and its gain-of-function mutants in cancer
Juan Liu et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2014)
HER2 aberrations in cancer: Implications for therapy
Min Yan et al.
CANCER TREATMENT REVIEWS (2014)
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Corine M. Beaufort et al.
PLOS ONE (2014)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress
D. Li et al.
CELL DEATH & DISEASE (2014)
Preferred binding of gain-of-function mutant p53 to bidirectional promoters with coordinated binding of ETS1 and GABPA to multiple binding sites
Catherine A. Vaughan et al.
ONCOTARGET (2014)
Towards Sustained Silencing of HER2/neu in Cancer By Epigenetic Editing
Fahimeh Falahi et al.
MOLECULAR CANCER RESEARCH (2013)
The ERBB network: at last, cancer therapy meets systems biology
Yosef Yarden et al.
NATURE REVIEWS CANCER (2012)
Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies
I. Goldstein et al.
CANCER GENE THERAPY (2011)
Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells
Dun Li et al.
MOLECULAR CANCER RESEARCH (2011)
Modulation of apoptosis by early human papillomavirus proteins in cervical cancer
A. Lagunas-Martinez et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2010)
Blinded by the Light: The Growing Complexity of p53
Karen H. Vousden et al.
CELL (2009)
Cell Lines as Candidate Reference Materials for Quality Control of ERBB2 Amplification and Expression Assays in Breast Cancer
Yan Xiao et al.
CLINICAL CHEMISTRY (2009)
A Negative Feedback Regulatory Loop Associates the Tyrosine Kinase Receptor ERBB2 and the Transcription Factor GATA4 in Breast Cancer Cells
Guoqiang Hua et al.
MOLECULAR CANCER RESEARCH (2009)
Unraveling the Biologic and Clinical Complexities of HER2
John W. Park et al.
CLINICAL BREAST CANCER (2008)
The combined immunodetection of AP-2 alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors
Abdelkader Allouche et al.
BREAST CANCER RESEARCH (2008)
An EGR2/CITED1 transcription factor complex and the 14-3-3σ tumor suppressor are involved in regulating ErbB2 expression in a transgenic-Mouse model of human breast cancer
Rachelle L. Dillon et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer
Anita Langerod et al.
BREAST CANCER RESEARCH (2007)
Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors
Marissa V. Powers et al.
ENDOCRINE-RELATED CANCER (2006)
ErbB2 overexpression in p53-inactivated mammary epithelial cells
Jin Won Yang et al.
FEBS LETTERS (2006)
Regulation of the p53 transcriptional activity
G Liu et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2006)
P53 and breast cancer, an update
Marc Lacroix et al.
ENDOCRINE-RELATED CANCER (2006)
Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells
L Delacroix et al.
DNA AND CELL BIOLOGY (2005)
HER2 expression in cervical cancer as a potential therapeutic target -: art. no. 59
A Chavez-Blanco et al.
BMC CANCER (2004)
被撤回的出版物: Transactivation of the EGR1 gene contributes to mutant p53 gain of function (Retracted article. See vol. 79, pg. 2085, 2019)
L Weisz et al.
CANCER RESEARCH (2004)
The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer
SB Bull et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line
KT Chan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Cell cycle arrest and apoptosis induction by activator protein 2α (AP-2α) and the role of p53 and p21WAF1/CIP1 in AP-2α-mediated growth inhibition
N Wajapeyee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Tumor suppressor activity of AP2α mediated through a direct interaction with p53
LA McPherson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
p53-dependent downregulation of metastasis-associated laminin receptor
M Modugno et al.
ONCOGENE (2002)
Regulation of HER2/Neu promoter activity by the ETS transcription factor, ER81
DG Bosc et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2002)
Dynamic chromatin remodeling on the HER2 promoter in human breast cancer cells
SK Mishra et al.
FEBS LETTERS (2001)
Update on HER-2 as a target for cancer therapy -: The ERBB2 promoter and its exploitation for cancer treatment
HC Hurst
BREAST CANCER RESEARCH (2001)
The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis
XM Xing et al.
NATURE MEDICINE (2000)
Share Paper
